Limited Competition: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant for the Clinical and Translational Science Awards Program

The Limited Competition Ruth L Kirschstein National Research Service Award Institutional Research Training Grant for the Clinical and Translational Science Awards Program is a federally funded opportunity administered by the National Institutes of Health within the U.S. Department of Health and Human Services. Specifically aligned with the National Center for Advancing Translational Sciences, this program operates under the broader Clinical and Translational Science Awards Program, which is mandated by Congress to strengthen the national infrastructure for translating scientific discoveries into practical health solutions. The initiative supports a coordinated network of academic medical centers that collaborate to accelerate the movement of research findings from laboratory environments into clinical applications and community health improvements. The primary purpose of this funding opportunity is to support institutional research training programs that prepare both predoctoral and postdoctoral scholars in clinical and translational science. The grant is designed to build a highly skilled workforce capable of advancing innovations in diagnostics, treatments, and health interventions. Through structured training environments, institutions are expected to provide mentorship, interdisciplinary collaboration, and access to resources that enable trainees to develop competencies necessary for translational research careers. The program emphasizes strengthening institutional capacity to deliver high quality training aligned with national health priorities. Funding under this opportunity is expected to support a range of allowable activities associated with research training, including stipends, tuition support, trainee related expenses, and program administration in accordance with NIH NRSA guidelines and federal regulations. Awards are governed by the Public Health Service Act and adhere to federal cost principles outlined in 2 CFR Part 200. While specific funding levels and award amounts are not disclosed in the forecast notice, expenditures must align with NIH standards for institutional training grants and are subject to agency oversight and compliance requirements. Eligibility for this opportunity is highly restricted and limited to organizations that have successfully secured funding under the Clinical and Translational Science Awards UM1 Notice of Funding Opportunity PAR 24 272 or its subsequent iterations. This creates a closed, competitive environment in which only established CTSA award recipients are invited to apply. As such, the applicant pool is composed primarily of academic medical centers and research institutions with demonstrated capacity in translational science infrastructure and training. The application process follows NIH standard submission and peer review procedures. Eligible institutions will be invited to submit applications, which will then undergo rigorous scientific and programmatic evaluation. Applications are assessed based on merit, training environment quality, program design, and alignment with translational science objectives. Only applications that meet high standards of excellence will be considered for funding. While specific application components are not detailed in the forecast, applicants can expect requirements typical of NIH training grants, including detailed program plans, trainee selection criteria, mentoring frameworks, and evaluation strategies. The timeline for this opportunity is currently in a forecast stage, with an estimated posting date in early September 2026 and an anticipated application due date of January 25 2027. Awards are expected to be made by mid December 2027, with project start dates aligned to the award timeline. As a forecasted limited competition, this opportunity represents an early engagement phase, allowing eligible institutions to prepare in advance of the official funding announcement. Questions regarding the program may be directed via email to the Division of Clinical Innovation at the National Center for Advancing Translational Sciences.